Plozasiran

Phase 3

Arrowhead Pharmaceuticals, Inc. (ARWR)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Familial Chylomicronemia

View Full Landscape

Drug Information

Target Indication

Familial Chylomicronemia

Clinical Trial

NCT05089084

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/19/2026

Redemplo

Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ARWR

Arrowhead Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Plozasiran InjectionPhase 3

Severe Hypertriglyceridemia

zodasiran InjectionPhase 3

Homozygous Familial Hypercholesterolemia

ARO-CFBPhase 2

IgA Nephropathy

ARO-APOC3Phase 2

Mixed Dyslipidemia

ARO-MMP7 Inhalation SolutionPhase 2

Idiopathic Pulmonary Fibrosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts